Loading clinical trials...
Loading clinical trials...
A Phase I/II Open-label Study of Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (CIT) in Subjects With Advanced Soft Tissue and Bone Sarcomas Receiving Gemcitabine and Docetaxel Chemotherapy
Conditions
Interventions
Eltrombopag
Locations
1
United States
Duke Cancer Center
Durham, North Carolina, United States
Start Date
April 1, 2012
Primary Completion Date
March 1, 2013
Completion Date
March 1, 2013
Last Updated
April 2, 2014
NCT07479732
NCT07144254
NCT06541262
NCT05235165
NCT04851119
NCT04698785
Lead Sponsor
Duke University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions